(95 days)
Not Found
Not Found
No
The device description details a standard TENS stimulator with a fixed frequency and adjustable amplitude, and there is no mention of AI or ML in the document.
Yes
The device is indicated for use as an adjunctive therapy in reducing pain and symptoms associated with osteoarthritis of the knee, which is a therapeutic purpose.
No
The device is indicated for use as an adjunctive therapy in reducing pain and improving the knee's condition, which are therapeutic actions, not diagnostic ones.
No
The device description explicitly states it is a "rechargeable battery operated TENS stimulator" and utilizes a "voltage regulated output circuit," indicating it is a hardware device that generates electrical pulses.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is to reduce pain and symptoms associated with osteoarthritis of the knee and improve the knee as assessed by a physician's global evaluation. This is a therapeutic use, not a diagnostic one.
- Device Description: The device is a TENS stimulator that applies electrical signals to the knee and thigh. This is a physical intervention, not a test performed on biological samples.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), detecting specific analytes, or providing diagnostic information about a patient's condition based on in vitro testing.
IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This device does not fit that description.
N/A
Intended Use / Indications for Use
The Bionicare Stimulator, Model BIO-1000, is indicated for use in relief of signs and symptoms of osteoarthritis of the knee based on scientific evidence from a multi-center. prospective, parallel, double-blinded, randomized, placebo device controlled clinical study that demonstrated significant improvement in the patient's self evaluation of pain and the physician's global evaluation of the active device treated knee.
The Bionicare® Stimulator System Model BIO-1000™ is indicated for use as an adjunctive therapy in reducing the level of pain and symptoms associated with osteoarthritis of the knee and for overall improvement of the knee as assessed by the physician's global evaluation (see clinical studies).
Product codes (comma separated list FDA assigned to the subject device)
NYN
Device Description
The Bionicare® Stimulator, Model BIO-1000 is a rechargeable battery operated TENS stimulator that utilizes a voltage regulated output circuit to generate a spike-shaped pulse with an adjustable amplitude of 0-12 volts peak and repeating at a single fixed frequency of 100 + 5 Hertz. Electrodes are applied to the knee and thigh using a standard electrode gel, Spectra 360 (Parker Laboratories NDC 341-0012-08), The signal is applied across the cathodic knee electrode and the anodic thigh electrode.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Knee and thigh
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The findings of this multi-center, prospective, parallel, double-blinded, randomized, placebo device controlled study demonstrate that the Bionicare Stimulator when used daily is safe and effective in the treatment of the signs and symptoms of osteoarthritis of the knee.
Safety: There were no reports of unanticipated adverse effects in this study. As anticipated, skin rash appeared in both the active and placebo device group, 39% and 27% respectively. The rash was transient and completely resolved after stopping or changing the electrode gel. The rash appears to be due to the sustained use of the electrode gel. The observed frequency of skin reactions reported herein appear similar to those reported in the literature for studies of TENS and muscle stimulator devices using comparable gels. Propylene glycol, a common ingredient in approved gels, is a skin irritant that may be in part the cause of these reactions.
Effectiveness: Daily treatment with the Bionicare stimulator resulted in a clinically relevant and statistically significant reduction in the signs and symptoms in the knees of patients affected by osteoarthritis. A repeated measures analysis of the primary clinical outcome data collected in this study demonstrated significant improvements in the Bionicare active device group compared to the placebo device group for the physician's global evaluation of the treated knee and the patient's evaluation of pain in the treated knee. The significant improvements for these clinical outcomes were reported both in terms of the absolute change and their percentage of change. The patient's self evaluation of knee function was not statistically significant, but showed trends favoring the active device group. Secondary efficacy outcome measures showed trends favoring the active device group. In particular, the trends in the measure of morning stiffness, knee tenderness and knee circumference favored the active device group.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 882.5890 Transcutaneous electrical nerve stimulator for pain relief.
(a)
Identification. A transcutaneous electrical nerve stimulator for pain relief is a device used to apply an electrical current to electrodes on a patient's skin to treat pain.(b)
Classification. Class II (performance standards).
0
JUL 2 2 1997
510(k) SUMMARY Bionicare® Stimulator System, Model BIO-1000 April 15, 1997
This summary is provided in accordance with the Safe Medical Devices Act of 1990 (SMDA). The information provided in the 510(k), premarket notification was in accordance with 21 CFR & 807,87 and the SMDA.
Submitter of 510(k) and Manufacturer 1.0
Murray Electronics 260 Schilling Circle Hunt Valley, MD 21031
| Attention: | Kent C. Hoffman |
|---|---|
| Telephone: | 410 771-0380 extension 231 |
| Facsimile: | 410 771-5576 |
2.0 Name of Device
2.1 Trade/Proprietary Name
Bionicare® Stimulator System, Model BIO-1000
2.2 Common/Usual Name
TENS (Transcutaneous Electrical Nerve Stimulator)
2.3 Classification Name
Transcutaneous electrical nerve stimulator for pain relief (21CFR§ 882.5890, class II).
3.0 Reason for Submitting the 510(k)
We are submitting this 510(k) to notify FDA of our desire to commercially distribute for the first time the Bionicare® Stimulator System, Model BIO-1000.
4.0 Device Description
The Bionicare® Stimulator, Model BIO-1000 is a rechargeable battery operated TENS stimulator that utilizes a voltage regulated output circuit to generate a spike-
1
shaped pulse with an adjustable amplitude of 0-12 volts peak and repeating at a single fixed frequency of 100 + 5 Hertz. Electrodes are applied to the knee and thigh using a standard electrode gel, Spectra 360 (Parker Laboratories NDC 341-0012-08), The signal is applied across the cathodic knee electrode and the anodic thigh electrode.
5.0 Indications for Use
The Bionicare Stimulator, Model BIO-1000, is indicated for use in relief of signs and symptoms of osteoarthritis of the knee based on scientific evidence from a multi-center. prospective, parallel, double-blinded, randomized, placebo device controlled clinical study that demonstrated significant improvement in the patient's self evaluation of pain and the physician's global evaluation of the active device treated knee.
6.0 Substantial Equivalence
The Bionicare is substantially equivalent to legally marketed predicate TENS devices. The indications for use and technological characteristics of the Bionicare® Stimulator System, Model BIO-1000 and the three legally marketed predicate devices cited below are substantially equivalent. As summarized in Table A, all the devices are electrical stimulators operating in substantially equivalent output ranges with comparable specifications. Each of the devices is battery powered and has adjustable output amplitudes. The output signals are all monophasic waveforms. The BIO-1000 has a single channel that has a fixed frequency and fixed pulse width in comparison to the predicate single and dual channel stimulators that have variable frequency and variable pulse width. Each device is capable of operating at a frequency of 100 Hertz. The electrical characteristics and the maximum charge of the output pulse of the Bionicare meet the safety and effectiveness requirements of the American National Standards Institute Standard for Transcutaneous Electrical Nerve Stimulators ANSI/AAMI NS4-1985, items 3.1 - 3.1.2.1, 3.2.2 - 3.2.4, 4.2.2 - 4.2.4.
2
| Table A |
|---|
| Technological Characteristics |
| Bionicare vs. Predicate Devices |
| Applicant Device | Predicate Device | Predicate Device | Predicate Device | |
|---|---|---|---|---|
| Manufacturer | Murray Electronics | Verite | Medgeneral | Medgeneral |
| Device | Bionicare Stimulator | Veri/PPR | Miniceptor | Miniceptor |
| Model No. | BIO-1000 | #800 | I | II |
| Output | ||||
| Voltage | 0-12 volts | 0-67 volts | 0-100 volts | 0-90 volts |
| Frequency | 100 Hertz | 1-125 Hertz | 25-100 Hertz | 25-100 Hertz |
| Pulse Width | .64 ms1 | .05 - .50 ms2 | .04 - .10 ms3 | .04 - .10 ms3 |
| Waveform | monophasic | |||
| spike-pulse | monophasic | |||
| sloped-pulse | monophasic | |||
| square-pulse | monophasic | |||
| square-pulse | ||||
| Pulse Charge | ||||
| Max | 20 $ μ C $ | NA5 | NA | NA |
| ANSI NS44 | Meets | NA | NA | NA |
| Channels | single | dual (single control) | single | dual |
| Battery Power | 12 v rechargeable | 67.5 v | rechargeable | rechargeable |
| Dimensions | 13.2 x 8.5 x 4.5 cm | 10.8 x 6.4 x 3.2 cm | 10.2 x 5.1 x 2.6 cm | 10.2 x 5.1 x 2.6 cm |
| Weight | ||||
| (Less Battery) | 235 grams | 237 grams | 176 grams | 179 grams |
| Charger | yes | no | yes | yes |
1 Pulse width fixed, measured at 50% pulse amplitude
2 Pulse width variable, range in product literature
3 Pulse width adjustable, range in product literature
4 The maximum charge per pulse meets the safety and effectiveness requirements of ANSI/AAMI NS4-1985, items 3.1-3.1.2.1, 3.2-3.2.5, 4.1-4.2.3.2
5 NA - Not Available from the data found.
The descriptive characteristics presented were precise enough to ensure the substantial equivalence of the Bionicare to legally marketed predicate devices. The descriptive characteristics included the data provided in the device comparison table above, as well as, the findings of performance and clinical testing. In particular, the performance data provides greater detail regarding the Bionicare's electrical characteristics, its conformance with voluntary standards and its safety and efficacy, as reported in a double-blinded, placebo device controlled study.
The findings of this multi-center, prospective, parallel, double-blinded, randomized, placebo device controlled study demonstrate that the Bionicare Stimulator when used daily is safe and effective in the treatment of the signs and symptoms of osteoarthritis of the knee. These findings are summarized below.
3
Safety
There were no reports of unanticipated adverse effects in this study. As anticipated, skin rash appeared in both the active and placebo device group, 39% and 27% respectively. The rash was transient and completely resolved after stopping or changing the electrode gel. The rash appears to be due to the sustained use of the electrode gel. The observed frequency of skin reactions reported herein appear similar to those reported in the literature for studies of TENS and muscle stimulator devices using comparable gels. Propylene glycol, a common ingredient in approved gels, is a skin irritant that may be in part the cause of these reactions.
Effectiveness
Daily treatment with the Bionicare stimulator resulted in a clinically relevant and statistically significant reduction in the signs and symptoms in the knees of patients affected by osteoarthritis. A repeated measures analysis of the primary clinical outcome data collected in this study demonstrated significant improvements in the Bionicare active device group compared to the placebo device group for the physician's global evaluation of the treated knee and the patient's evaluation of pain in the treated knee. The significant improvements for these clinical outcomes were reported both in terms of the absolute change and their percentage of change. The patient's self evaluation of knee function was not statistically significant, but showed trends favoring the active device group. Secondary efficacy outcome measures showed trends favoring the active device group. In particular, the trends in the measure of morning stiffness, knee tenderness and knee circumference favored the active device group.
4
Image /page/4/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo consists of a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged around the circumference. Inside the circle is a stylized image of an eagle with three lines representing its body and wings.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville, Maryland 20850
JUN - 8 2006
Mr. Kent C. Hoffman Director, Research and Development Murray Electronics 260 Schilling Circle Hunt Valley, MD 21031
K971437 Bionicare Stimulator System Model BIO-1000 Regulatory Class: II Product Code: NYN Dated: July 18, 1997 Received: July 21, 1997
Dear Mr. Hoffman:
This letter corrects our substantially equivalent letter of July 22, 1997.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Eederal Register.
5
Page 2 - Mr. Kent C. Hoffman
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good minned to: 10g.stration and institute (s as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
Mark McMillan
Mark N. Melkerson, M.S Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
Image /page/5/Picture/7 description: The image shows a circular logo for the FDA Centennial. The logo features the letters "FDA" in a bold, sans-serif font, stacked on top of the word "Centennial". Above the letters "FDA" are the numbers "1906-1906". Below the word "Centennial" are three stars. The entire logo is surrounded by a circular border with text that is difficult to read due to the image quality.
Protecting and Promoting Public Health
6
Device Name
Bionicare® Stimulator System, Model BIO-1000™
Indications For Use
The Bionicare® Stimulator System Model BIO-1000™ is indicated for use as an adjunctive therapy in reducing the level of pain and symptoms associated with osteoarthritis of the knee and for overall improvement of the knee as assessed by the physician's global evaluation (see clinical studies).
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE) Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use: (Per 21 CFR 801.109)
Thomas J. Callahon
(Division Sign-Off) Division of Cardiovascular, Respiratory, and Neurological Devices
510(k) Number _
(Optional Format 1-2-96)
5